You need to be logged in to see the full monograph.

USE OF HYDROXYCHLOROQUINE IN PREGNANCY

Date of issue: July 2025, Version: 1.0

bumps logo
A corresponding patient information leaflet on USE OF HYDROXYCHLOROQUINE IN PREGNANCY is available.

Hydroxychloroquine (HCQ) is a quinine derivative indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus (SLE), and dermatological conditions caused or aggravated by sunlight.

Guidance from the British Society for Rheumatology (BSR) states that HCQ can be used throughout pregnancy at doses of ≤400mg/day and is a drug of choice for women with rheumatic disease who are planning a pregnancy.

A single study found that daily doses of HCQ ≥400mg were associated with a 30% increase in risk of congenital malformation (equating to an ~4% malformation risk following exposure), whereas lower doses were not associated with increased risk. These data are likely confounded by maternal disease severity and are of limited relevance to most patients as HCQ doses above 400mg/day are not generally recommended for the treatment of rheumatic disease. The available data overall do not demonstrate that HCQ exposure in pregnancy increases the risks of miscarriage, stillbirth, preterm delivery (PTD), or low infant birth weight. Protective effects against PTD have been inconsistently observed. HCQ treatment of SLE and/or antiphospholipid syndrome during pregnancy has been associated with reduced disease flare and improved pregnancy and neonatal outcomes, including reductions in preterm birth, intrauterine death, neonatal lupus, and congenital heart block. There are limited but reassuring data relating to childhood neurodevelopment following HCQ exposure.

Exposure to HCQ at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, women with rheumatic disease may require closer monitoring during pregnancy including serial fetal growth measurement. Other risk factors which could independently increase the risk of adverse pregnancy outcome may also be present in individual cases and should be considered when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from UKTIS.org to ensure you are using the most up-to-date version.